Impact of HIV and its treatment on reverse cholesterol transport

Not Applicable

Completed

• Conditions: HIV; Atherosclerosis; Infection - Acquired immune deficiency syndrome (AIDS / HIV); Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12605000494639
• Lead Sponsor: ational Health and Medical Research Council of Australia (grants # 317811 and 317810(DS)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-23
• Study Completion: 2007-06-01
• Last Update Posted: 28 June 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 49

Inclusion Criteria

Male patients with HIV infection. 3 groups of 50 patients each. HIV infected patients, naive to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months). HIV-infected patients, PI naive, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen). HIV-infected patients naive to ARV therapy, initiating NNRTI-containing regimen.

Exclusion Criteria

Treatment with any form of lipid lowering drugs, including fish oils. Body Mass Index greater than 27.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on reverse cholesterol transport in HIV-infected patients in a prospective study over a 12 month period.[12 months]

Secondary Outcome Measures

Name	Time	Method
1.To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport in HIV-infected patients.[Over a 12 month period.];2.To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on endothelial function in HIV-infected patients.[Over a 12 month period.];3. To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on intima-media thickness (atherosclerotic development) in HIV-infected patients.[Over a 12 month period.];4.To analyse factors which determine the rate of reverse cholesterol transport in HIV patients naive to therapy and during treatment with HAART.[N/A];5. To correlate use of protease inhibitors with defects in reverse cholesterol transport and clinical markers of atherosclerosis.[N/A]